NURS 6630 week 9 Blog SUBSTANCE USE, ADDICTION/IMPULSE CONTROL DISORDER

SUBSTANCE USE, ADDICTION/IMPULSE CONTROL DISORDER

In this Blog, you will have the opportunity to teach your peers about a specific substance use and/or addiction/impulse control disorder. A Blog is a conversational, informal written piece on a topic. Your faculty will assign you a particular illness and the approved treatment for the illness to create a presentation to share with your peers.

Construct a Blog post, not to exceed 1,500–2,000 words, written for a PMHNP provider audience to post in the Discussion area.

Although you are not required to respond to colleagues, collegial discussion is welcome. Also, it will be important for you to read your peers’ Blog posts in order to learn about all of the medications on the assigned list.

You will be assigned from the following list:

  • Opioid Use Disorder
    • Vivitrol
    • Suboxone
    • Methadone
    • Lofexidine
  • Alcohol Use Disorder
    • Acamprosate
    • Naltrexone
    • Disulfiram
    • Phenobarbital (seizure control due to alcohol withdrawal)
    • Chlordiazepoxide
  • Cannabis Use Disorder
    • Nefazodone*
    • Fluoxetine*
    • Gabapentin*
    • Buspirone*
  • Stimulant Use Disorder (cocaine, methamphetamine)
    • Antipsychotic Medications*
    • Combination Injectable Naltrexone*
    • Bupropion*
    • Gabapentin*
  • Tobacco Use Disorder
    • Nicotine replacement patch
    • Nicotine replacement gum
    • Nicotine replacement inhaler
    • Zyban
  • Sedative/Hypnotic Anxiolytic Use Disorder
    • Gabapentin*
    • Buspirone*
    • Flumazenil*
    • Trazodone*
  • Binge Eating Disorder (BED)
    • Lisdexamphetamine

*Indicates not FDA approved.

RESOURCES

Be sure to review the Learning Resources before completing this activity.
Click the weekly resources link to access the resources.

WEEKLY RESOURCES

BY DAY 5 OF WEEK 9

Post your Blog response by doing the following:

  • Identify the substance or addiction with discussion on pertinent diagnostic criteria for the use disorder.
  • Identify the street names of the substance for the use disorder.
  • Describe how someone can use or abuse the substance (oral, smoke, IV, etc.).
  • Describe the symptoms of someone under the influence of this substance.
  • Describe the symptoms of someone under the withdrawal of this substance.

After describing the substance, discuss the treatment recommendations by doing the following:

  • Identify the first-line treatment options.
  • Identify the FDA-approved medications for the substance.

Note: If there are no FDA-approved medications, describe any evidenced-based, clinically acceptable off-label medications to treat the illness.

  • Identify the proposed mechanisms of action for the medication to treat the illness.
  • Describe the common side effects of the medication.
  • Describe how the patient should take the medication.
  • Identify any baseline and/or ongoing tests and assessment(s) needed when taking the medication.
  • Describe the non-pharmacologic intervention recommendations.

This Assignment requires a minimum of three (3) peer-reviewed, evidence-based scholarly references outside of course Learning Resources.

Note: You will need to include the APA formatting citation of all references used with a Reference list.You will be assigned from the following list:

  • Opioid Use Disorder  – LAST NAME ENDS IN  A-D
    • Vivitrol
    • Suboxone
    • Methadone
    • Lofexidine
  • Alcohol Use Disorder – LAST NAME ENDS  IN E-H
    • Acamprosate
    • Naltrexone
    • Disulfiram
    • Phenobarbital (seizure control due to alcohol withdrawal)
    • Chlordiazepoxide
  • Cannabis Use Disorder – LAST NAME ENDS IN I-L
    • Nefazodone*
    • Fluoxetine*
    • Gabapentin*
    • Buspirone*
  • Stimulant Use Disorder (cocaine, methamphetamine) LAST NAMES ENDS IN M- Q
    • Antipsychotic Medications*
    • Combination Injectable Naltrexone*
    • Bupropion*
    • Gabapentin*
  • Tobacco Use Disorder Nicotine replacement patch – LAST NAME ENDS IN R-T
    • Nicotine replacement gum
    • Nicotine replacement inhaler
    • Zyban
  • Sedative/Hypnotic Anxiolytic Use Disorder -LAST NAME ENDS IN U-W
    • Gabapentin*
    • Buspirone*
    • Flumazenil*
    • Trazodone*
  • Binge Eating Disorder (BED) LAST NAME ENDS IN X-Z
    • Lisdexamphetamine

*Indicates not FDA approved.

 Solution:

Sedative/Hypnotic Anxiolytic Use Disorder

o Gabapentin*
o Buspirone*
o Flumazenil*
o Trazodone* is the medication I’m assigned.

 

Sedative/Hypnotic Anxiolytic Use Disorder

            Sedatives (hypnotics) are drugs used to treat insomnia and other conditions while anxiolytics are drugs used to treat anxiety disorders including generalized anxiety and panic disorders (Simone & Bobrin, 2023). Due to their sedating effects, these drugs are at risk of being misused and abused, resulting in unwanted and possibly deadly consequences. Benzodiazepines (BZDs) (e.g., diazepam, alprazolam, lorazepam), commonly prescribed for insomnia, anxiety, and depression are among the most commonly misused and abused hypnotic anxiolytics (FDA, n.d). According to Gozda et al. (2022), chronic use of sedative/ hypnotics anxiolytics results in impaired daytime functioning, increased risk of falls and injury, motor vehicle accidents, physical dependence, and cognitive impairment, with higher doses, prolonged use, history of psychiatric illness, and short-acting BZDs being associated with a higher risk of dependence, abuse, withdrawal, and rebound symptoms (Gozda et al., 2022). This blog discusses BZD use disorder including diagnostic criteria, symptoms, withdrawal symptoms, and treatment options (pharmacological and non-pharmacological).

Diagnostic Criteria for Sedative/Hypnotic Anxiolytic Use Disorder

The diagnostic criteria for sedative/ hypnotic anxiolytic use disorder as provided by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) includes (A) problematic patterns of using sedatives, hypnotics, or anxiolytics that cause clinically significant distress or impairment, characterized by two or more of the following symptoms that manifest within 12 months (American Psychiatric Association [APA], 2022).

  1. Use of substance in larger quantities or for prolonged periods than intended
  2. Persistent desire or unfruitful attempts to control or stop substance use
  3. Spending significant time obtaining, using, or recovering from the substance’s effects
  4. Strong craving to use the substance
  5. Recurrent substance use that causes impaired functioning at home, school, or work
  6. Continued substance use even when it persistently causes frequent problems in one’s social or interpersonal life due to its side effects
  7. Giving up on or reducing important occupational, social, or recreational activities due to substance use